Bioinformatics analysis of the CDK2 functions in neuroblastoma

Bo,Lijuan; Wei,Bo; Wang,Zhanfeng; Kong,Daliang; Gao,Zheng; Miao,Zhuang

doi:10.3892/mmr.2017.8368

Bioinformatics analysis of the CDK2 functions in neuroblastoma

Authors:
- Lijuan Bo
- Bo Wei
- Zhanfeng Wang
- Daliang Kong
- Zheng Gao
- Zhuang Miao
View Affiliations

Affiliations: Department of Infections, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Neurosurgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Orthopaedics, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: December 29, 2017 https://doi.org/10.3892/mmr.2017.8368
Pages: 3951-3959

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to elucidate the potential mechanism of cyclin-dependent kinase 2 (CDK2) in neuroblastoma progression and to identify the candidate genes associated with neuroblastoma with CDK2 silencing. The microarray data of GSE16480 were obtained from the gene expression omnibus database. This dataset contained 15 samples: Neuroblastoma cell line IMR32 transfected with CDK2 shRNA at 0, 8, 24, 48 and 72 h (n=3 per group; total=15). Significant clusters associated with differentially expressed genes (DEGs) were identified using fuzzy C‑Means algorithm in the Mfuzz package. Gene ontology and pathway enrichment analysis of DEGs in each cluster were performed, and a protein‑protein interaction (PPI) network was constructed. Additionally, functional annotation of DEGs in clusters was performed for the detection of transcription factors and tumor‑associated genes. A total of 4 clusters with significant change tendency and 1,683 DEGs were identified. The hub nodes of the PPI network constructed by DEGs in Cluster 1, Cluster 2, Cluster 3 and Cluster 4 were MDM2 oncogene, E3 ubiquitin protein ligase (MDM2), cyclin‑dependent kinase 1 (CDK1), proteasome (prosome, macropain) 26S subunit, non‑ATPase, 14 (PSMD14) and translocator protein (18 kDa) (TSPO) respectively. These genes were significantly enriched in the p53 signaling pathway, cell cycle, proteasome and systemic lupus erythematosus pathways. MDM2, CDK1, PSMD14 and TSPO may be key target genes of CDK2. CDK2 may have key functions in neuroblastoma progression by regulating the expression of these genes.

View Figures

View References

1	Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM and Peters S; ESMO Guidelines Working Group, : Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 3 Suppl 25:iii27–iii39. 2014. View Article : Google Scholar
2	George RE, Sanda T, Hanna M, Fröhling S, Luther W II, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, et al: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 455:975–978. 2008. View Article : Google Scholar : PubMed/NCBI
3	Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 455:930–935. 2008. View Article : Google Scholar : PubMed/NCBI
4	George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA and Diller L: High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol. 24:2891–2896. 2006. View Article : Google Scholar : PubMed/NCBI
5	Schwab M, Varmus HE, Bishop JM, Grzeschik KH, Naylor SL, Sakaguchi AY, Brodeur G and Trent J: Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature. 308:288–291. 1984. View Article : Google Scholar : PubMed/NCBI
6	Cole MD and Cowling VH: Transcription-independent functions of MYC: Regulation of translation and DNA replication. Nat Rev Mol Cell Biol. 9:810–815. 2008. View Article : Google Scholar : PubMed/NCBI
7	Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A and Shohet JM: The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA. 102:pp. 731–736. 2005; View Article : Google Scholar : PubMed/NCBI
8	Meyer N, Kim SS and Penn LZ: The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol. 16:275–287. 2006. View Article : Google Scholar : PubMed/NCBI
9	Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R and Caron HN: Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci USA. 106:pp. 12968–12973. 2009; View Article : Google Scholar : PubMed/NCBI
10	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI
11	Malumbres M and Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci. 30:630–641. 2005. View Article : Google Scholar : PubMed/NCBI
12	Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 24:1770–1783. 2006. View Article : Google Scholar : PubMed/NCBI
13	Hall C, Nelson DM, Ye X, Baker K, DeCaprio JA, Seeholzer S, Lipinski M and Adams PD: HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression. Mol Cell Biol. 21:1854–1865. 2001. View Article : Google Scholar : PubMed/NCBI
14	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
15	Futschik ME and Carlisle B: Noise-robust soft clustering of gene expression time-course data. J Bioinform Comput Biol. 3:965–988. 2005. View Article : Google Scholar : PubMed/NCBI
16	Kumar L and Futschik E M: Mfuzz: A software package for soft clustering of microarray data. Bioinformation. 2:5–7. 2007. View Article : Google Scholar : PubMed/NCBI
17	von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P and Snel B: STRING: A database of predicted functional associations between proteins. Nucleic Acids Res. 31:258–261. 2003. View Article : Google Scholar : PubMed/NCBI
18	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
19	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI
20	Zhao M, Sun J and Zhao Z: TSGene: A web resource for tumor suppressor genes. Nucleic Acids Res. 41(Database Issue): D970–D976. 2013. View Article : Google Scholar : PubMed/NCBI
21	Chen JS, Hung WS, Chan HH, Tsai SJ and Sun HS: In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma. Bioinformatics. 29:420–427. 2013. View Article : Google Scholar : PubMed/NCBI
22	Slack A and Shohet JM: MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. Cell Cycle. 4:857–860. 2005. View Article : Google Scholar : PubMed/NCBI
23	Slack AD, Chen Z, Ludwig AD, Hicks J and Shohet JM: MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Cancer Res. 67:2448–2455. 2007. View Article : Google Scholar : PubMed/NCBI
24	Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
25	Meek DW and Knippschild U: Posttranslational modification of MDM2. Mol Cancer Res. 1:1017–1026. 2003.PubMed/NCBI
26	Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C and Lunec J: The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 197:93–98. 2003. View Article : Google Scholar : PubMed/NCBI
27	Elias B, Laine A and Ronai Z: Phosphorylation of MdmX by CDK2/Cdc2(p34) is required for nuclear export of Mdm2. Oncogene. 24:2574–2579. 2005. View Article : Google Scholar : PubMed/NCBI
28	Tanaka K: The proteasome: Overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci. 85:pp. 12–36. 2009; View Article : Google Scholar : PubMed/NCBI
29	Bonvini P, Nguyen P, Trepel J and Neckers LM: In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome. Oncogene. 16:1131–1139. 1998. View Article : Google Scholar : PubMed/NCBI
30	Kwak MK, Cho JM, Huang B, Shin S and Kensler TW: Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells. Free Radic Biol Med. 43:809–817. 2007. View Article : Google Scholar : PubMed/NCBI
31	Laetsch T, Liu X, Vu A, Sliozberg M, Vido M, Elci OU, Goldsmith KC and Hogarty MD: Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma. Cell Death Dis. 5:e10722014. View Article : Google Scholar : PubMed/NCBI
32	Goldsmith KC, Lestini BJ, Gross M, Ip L, Bhumbla A, Zhang X, Zhao H, Liu X and Hogarty MD: BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ. 17:872–882. 2010. View Article : Google Scholar : PubMed/NCBI
33	Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, Sliozberg M, Guo R, Zhao H, Reynolds CP and Hogarty MD: Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 72:2565–2577. 2012. View Article : Google Scholar : PubMed/NCBI
34	Liang J, Parchaliuk D, Medina S, Sorensen G, Landry L, Huang S, Wang M, Kong Q and Booth SA: Activation of p53-regulated pro-apoptotic signaling pathways in PrP-mediated myopathy. BMC Genomics. 10:2012009. View Article : Google Scholar : PubMed/NCBI
35	Goga A, Yang D, Tward AD, Morgan DO and Bishop JM: Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med. 13:820–827. 2007. View Article : Google Scholar : PubMed/NCBI
36	Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H and Meijer L: CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 27:5797–5807. 2008. View Article : Google Scholar : PubMed/NCBI
37	Chen Y, Tsai YH and Tseng SH: Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway. Surgery. 153:4–16. 2013. View Article : Google Scholar : PubMed/NCBI
38	Santamaría D, Barrière C, Cerqueira A, Hunt S, Tardy C, Newton K, Cáceres JF, Dubus P, Malumbres M and Barbacid M: Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 448:811–815. 2007. View Article : Google Scholar : PubMed/NCBI
39	Tetsu O and McCormick F: Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 3:233–245. 2003. View Article : Google Scholar : PubMed/NCBI
40	Casellas P, Galiegue S and Basile AS: Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int. 40:475–486. 2002. View Article : Google Scholar : PubMed/NCBI
41	Santidrián AF, Cosialls AM, Coll-Mulet L, Iglesias-Serret D, de Frias M, González-Gironès DM, Campàs C, Domingo A, Pons G and Gil J: The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells. Haematologica. 92:1631–1638. 2007. View Article : Google Scholar : PubMed/NCBI
42	Mendonça-Torres MC and Roberts SS: The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines. Cancer Biol Ther. 14:319–326. 2013. View Article : Google Scholar : PubMed/NCBI